Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue
Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue The Motley Fool
Covered in this story
Analyst targets on Amgen
- Wells Fargo: $432 → $430 by Oct 2027 · equal weight via MarketBeat
- Scotiabank: $432 → $500 by Oct 2027 · outperform via MarketBeat
- Cantor Fitzgerald: $432 → $440 by Oct 2027 · neutral via MarketBeat
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $AMGN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Amgen →Dalsna Finance is currently tracking 49 stories mentioning Amgen, the earliest published 30 Mar 2026.
Summary aggregated from The Motley Fool's public RSS feed. The full reporting belongs to The Motley Fool — please read it on their site.